See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is an antineoplastic agent, which means it is a drug that is used to treat cancer. It works by inhibiting the transcription factor SP1, which is involved in the regulation of many genes that are important for cell growth and survival [1].

In terms of its effect on immune cell function, lurbinectedin has been shown to have immunomodulatory properties. A study published in the journal Oncotarget found that lurbinectedin can induce the expression of PD-L1, a protein that helps tumor cells evade the immune system, on the surface of cancer cells [2]. This suggests that lurbinectedin may be able to enhance the effectiveness of immunotherapy drugs that target PD-L1, such as pembrolizumab and nivoluzumab.

Additionally, a study published in the journal Clinical Cancer Research found that lurbinectedin can increase the number of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment [3]. TILs are a type of immune cell that can recognize and kill cancer cells. This increase in TILs was associated with improved clinical outcomes in patients treated with lurbinectedin.

It is important to note that while these studies suggest that lurbinectedin has the potential to enhance immune cell function, more research is needed to fully understand its mechanisms of action and to determine the optimal way to combine it with other therapies.

In summary, lurbinectedin is an antineoplastic agent that has immunomodulatory properties and can increase the number of tumor-infiltrating lymphocytes in the tumor microenvironment, which can enhance the immune system's ability to recognize and kill cancer cells.

Sources:

1. <https://www.drugpatentwatch.com/drugs/lurbinectedin>
2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164032/>
3. <https://clincancerres.aacrjournals.org/content/26/12/3033>